Lecanemab Mechanism of Action: the First Alzheimer’s Drug that Works?
Lecanemab is an IgG1 monoclonal antibody that binds and eliminates building blocks of amyloid plaques in the brain, thus helping to slow progression of Alzheimer disease. Lacenemab: Discovery and Approval Lecanemab (brand name Leqembi) was discovered by BioArctic, a Swedish biopharmaceutical company, in collaboration with Eisai Co., Ltd. Since 2005 the team of Swedish biotech … Read more